Mr. Stewart will focus on advancing Commense’s lead program towards the clinic, growing the Company’s microbiome-based development capabilities and expanding its fundraising and business development efforts to fuel the growth of the Company.

He joins Commense with more than 20 years of experience in the biotechnology field, including over 15 years at Merrimack Pharmaceuticals, where he was instrumental in growing the company from a pre-clinical organisation to a commercial enterprise.  Under his leadership as Senior Vice President of Business Development and Head of Merrimack’s Commercial Business Unit, the company executed multiple partnership and licensing deals with a total value in excess of $1.5 billion.
 
“We are excited to have Tad on board as we build and develop our arsenal of paediatric microbiome-derived therapeutics,” said David Steinberg, Chief Innovation Officer at PureTech Health and Co-founder of Commense. “Tad brings extensive strategic and business development experience and has a proven track record of building value and deal-making.”